A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYAN1, a novel PHD-2 Inhibitor, following oral administration in healthy volunteers.

Trial Profile

A randomized, double-blind, placebo-controlled Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of ZYAN1, a novel PHD-2 Inhibitor, following oral administration in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs Desidustat (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; First in man
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 11 Jun 2015 Planned number of patients changed from 84 to 100 as reported by Australian New Zealand Clinical Trials Registry record.
    • 16 Feb 2015 According to a Zydus Cadila media release, part I of this study is completed and the multiple ascending dose study has been initiated.
    • 09 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top